Immunosuppressant prescription pattern and trend in kidney transplantation: A multicenter study in Korea

PLoS One. 2017 Aug 28;12(8):e0183826. doi: 10.1371/journal.pone.0183826. eCollection 2017.

Abstract

Background: The actual prescription pattern of immunosuppressive agents in kidney transplantation is unclear.

Methods: We investigated the pattern and trend of immunosuppressive treatment for kidney transplant patients in South Korea. A total of 636 patients at nine transplant centers were enrolled and followed for one year. We reviewed medical records and evaluated induction therapy, as well as the changing pattern and cause of maintenance therapy.

Results: Most patients (n = 621, 97.6%) received induction therapy often comprising basiliximab (n = 542, 85.2%). The triple therapy including calcineurin inhibitor, mycophenolic acid, and steroids was the major initial maintenance immunosuppression (n = 518, 81.4%), but its proportion decreased by 14% (81.4% to 67.5%) after 1 year. Almost 40% of patients changed immunosuppressive regimen during the 1-year follow-up, most often at an early period (60.2% within the first 4 months). The primary reason for the change was gastrointestinal discomfort (n = 113, 29.8%), followed by infection (112, 29.6%). The most common changing pattern was mycophenolic acid withdrawal (n = 155, 39.1%).

Conclusion: The initial immunosuppressive regimen is prone to change within the first year of kidney transplantation. Further studies are needed to evaluate the benefits and risks in patients who changed immunosuppressants.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Republic of Korea

Substances

  • Immunosuppressive Agents

Grants and funding

I confirm that this study was funded by Novartis Korea, Ltd. and protocol number was CERL080AKR10 (https://www.novartis.co.kr/). The authors who received the funding were JY, SJK, CDK, SHL, JSL, JKK, CWJ, CKO, CWY. The funder had a role of proposing a multicenter research and making 9 centers participate in the study. The funder did not serve on the editorial board of the journal and did not act as an expert witness in relevant legal proceedings. And the funder did not sit on a committee for an organization benefit from publication of the paper.